@vintweeta @DeptVetAffairs Evidence is now getting overwhelming that HF benefit is not due to SGLT2 inhibition, exciting work on NHE1 inhibition resulting in enhanced sarcomere function (see https://t.co/JHqcX5BnkK). In my mind, with LV dysfunction, mechan
#PubsaludMurcia Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes. https://t.co/hxIEdeHNB9
RT @JACCJournals: What can #AI teach us about the cardiac mechanism of action of #empagliflozin in #HFrEF patients with and without #diabet…
RT @JACCJournals: What can #AI teach us about the cardiac mechanism of action of #empagliflozin in #HFrEF patients with and without #diabet…
RT @JACCJournals: What can #AI teach us about the cardiac mechanism of action of #empagliflozin in #HFrEF patients with and without #diabet…
RT @EstebanDL: Proponen un intercambiador Sodio - hidrogeniones, como responsable de la mejoria de la empagliflozina en insuficiencia cardí…
Proponen un intercambiador Sodio - hidrogeniones, como responsable de la mejoria de la empagliflozina en insuficiencia cardíaca con y sin diabetes via: @alavallecobo https://t.co/1iZlKAIy6Q Estudio con dos moralejas 1. El sistema es complejo 2. @AKraseln
RT @almucastro01: Mediante #IA se demuestra el mecanismo principal por el cual empagliflozina produce beneficio ❤️ en ICFEr en DM y noDM: “…
RT @almucastro01: Mediante #IA se demuestra el mecanismo principal por el cual empagliflozina produce beneficio ❤️ en ICFEr en DM y noDM: “…
RT @JACCJournals: What can #AI teach us about the cardiac mechanism of action of #empagliflozin in #HFrEF patients with and without #diabet…
RT @almucastro01: Mediante #IA se demuestra el mecanismo principal por el cual empagliflozina produce beneficio ❤️ en ICFEr en DM y noDM: “…
RT @drdargaray: Revelando los mecanismos de los iSLGT2 en insuficiencia cardíaca usando inteligencia artificial. Parece que el bloqueo de…
The science of how empaglogizin works in HF https://t.co/TmK1glBkLk #HHS2019 https://t.co/eAQRl8rLzh
RT @almucastro01: Mediante #IA se demuestra el mecanismo principal por el cual empagliflozina produce beneficio ❤️ en ICFEr en DM y noDM: “…
RT @almucastro01: Mediante #IA se demuestra el mecanismo principal por el cual empagliflozina produce beneficio ❤️ en ICFEr en DM y noDM: “…
RT @JACCJournals: What can #AI teach us about the cardiac mechanism of action of #empagliflozin in #HFrEF patients with and without #diabet…
RT @JACCJournals: What can #AI teach us about the cardiac mechanism of action of #empagliflozin in #HFrEF patients with and without #diabet…
RT @JACCJournals: What can #AI teach us about the cardiac mechanism of action of #empagliflozin in #HFrEF patients with and without #diabet…
RT @almucastro01: Mediante #IA se demuestra el mecanismo principal por el cual empagliflozina produce beneficio ❤️ en ICFEr en DM y noDM: “…
RT @almucastro01: Mediante #IA se demuestra el mecanismo principal por el cual empagliflozina produce beneficio ❤️ en ICFEr en DM y noDM: “…
RT @almucastro01: Mediante #IA se demuestra el mecanismo principal por el cual empagliflozina produce beneficio ❤️ en ICFEr en DM y noDM: “…
RT @almucastro01: Mediante #IA se demuestra el mecanismo principal por el cual empagliflozina produce beneficio ❤️ en ICFEr en DM y noDM: “…
RT @almucastro01: Mediante #IA se demuestra el mecanismo principal por el cual empagliflozina produce beneficio ❤️ en ICFEr en DM y noDM: “…
RT @JACCJournals: What can #AI teach us about the cardiac mechanism of action of #empagliflozin in #HFrEF patients with and without #diabet…
RT @almucastro01: Mediante #IA se demuestra el mecanismo principal por el cual empagliflozina produce beneficio ❤️ en ICFEr en DM y noDM: “…
RT @almucastro01: Mediante #IA se demuestra el mecanismo principal por el cual empagliflozina produce beneficio ❤️ en ICFEr en DM y noDM: “…
RT @almucastro01: Mediante #IA se demuestra el mecanismo principal por el cual empagliflozina produce beneficio ❤️ en ICFEr en DM y noDM: “…
RT @almucastro01: Mediante #IA se demuestra el mecanismo principal por el cual empagliflozina produce beneficio ❤️ en ICFEr en DM y noDM: “…
RT @almucastro01: Mediante #IA se demuestra el mecanismo principal por el cual empagliflozina produce beneficio ❤️ en ICFEr en DM y noDM: “…
RT @almucastro01: Mediante #IA se demuestra el mecanismo principal por el cual empagliflozina produce beneficio ❤️ en ICFEr en DM y noDM: “…
RT @almucastro01: Mediante #IA se demuestra el mecanismo principal por el cual empagliflozina produce beneficio ❤️ en ICFEr en DM y noDM: “…
Mediante #IA se demuestra el mecanismo principal por el cual empagliflozina produce beneficio ❤️ en ICFEr en DM y noDM: “direct NHE1 blockade by empagliflozin ameliorated cardiomyocyte cell death by restoring expression of X-linked inhibitor of apoptosis”h
RT @JACCJournals: What can #AI teach us about the cardiac mechanism of action of #empagliflozin in #HFrEF patients with and without #diabet…
Cool work. Nice to have MOA for the observed SGLT2i’s benefit in HFrEF. Probably won’t be long before a trial is proposed for youth with DCM.
RT @JACCJournals: What can #AI teach us about the cardiac mechanism of action of #empagliflozin in #HFrEF patients with and without #diabet…
RT @JACCJournals: What can #AI teach us about the cardiac mechanism of action of #empagliflozin in #HFrEF patients with and without #diabet…
RT @JACCJournals: What can #AI teach us about the cardiac mechanism of action of #empagliflozin in #HFrEF patients with and without #diabet…
RT @JACCJournals: What can #AI teach us about the cardiac mechanism of action of #empagliflozin in #HFrEF patients with and without #diabet…
RT @JACCJournals: What can #AI teach us about the cardiac mechanism of action of #empagliflozin in #HFrEF patients with and without #diabet…
RT @JACCJournals: What can #AI teach us about the cardiac mechanism of action of #empagliflozin in #HFrEF patients with and without #diabet…
RT @JACCJournals: What can #AI teach us about the cardiac mechanism of action of #empagliflozin in #HFrEF patients with and without #diabet…
RT @drdargaray: Revelando los mecanismos de los iSLGT2 en insuficiencia cardíaca usando inteligencia artificial. Parece que el bloqueo de…
RT @JACCJournals: What can #AI teach us about the cardiac mechanism of action of #empagliflozin in #HFrEF patients with and without #diabet…
RT @JACCJournals: What can #AI teach us about the cardiac mechanism of action of #empagliflozin in #HFrEF patients with and without #diabet…
What can #AI teach us about the cardiac mechanism of action of #empagliflozin in #HFrEF patients with and without #diabetes? https://t.co/tSaWZIfLgi #JACCBTS @JavedButler1 https://t.co/xcnUpA7tkV
RT @drdargaray: Revelando los mecanismos de los iSLGT2 en insuficiencia cardíaca usando inteligencia artificial. Parece que el bloqueo de…
RT @DomingoPascualF: Estamos intentando descifrar los mecanismos del beneficio de los probablemente mal llamados iSGLT2, próximamente más h…
@dhekidney @ChristosArgyrop Apologies for late reply @dhekidney & am sure that Christos has advised by now. Like MRAs -reduction in apoptosis reported in @JACCJournals #JACCBTS Unraveling Molecular Mechanism of Action of Empagliflozin in #HFrEF With
RT @drdargaray: Revelando los mecanismos de los iSLGT2 en insuficiencia cardíaca usando inteligencia artificial. Parece que el bloqueo de…
RT @drdargaray: Revelando los mecanismos de los iSLGT2 en insuficiencia cardíaca usando inteligencia artificial. Parece que el bloqueo de…
RT @DomingoPascualF: Estamos intentando descifrar los mecanismos del beneficio de los probablemente mal llamados iSGLT2, próximamente más h…
Revelando los mecanismos de los iSLGT2 en insuficiencia cardíaca usando inteligencia artificial. Parece que el bloqueo del cotransportador Na/H (y su efecto anti-apoptosis) son el principal mecanismo @cardiogax @DanielSierraMD8 @gonzaeperez @paomorejon
RT @DomingoPascualF: Estamos intentando descifrar los mecanismos del beneficio de los probablemente mal llamados iSGLT2, próximamente más h…
RT @DomingoPascualF: Estamos intentando descifrar los mecanismos del beneficio de los probablemente mal llamados iSGLT2, próximamente más h…
RT @DomingoPascualF: Estamos intentando descifrar los mecanismos del beneficio de los probablemente mal llamados iSGLT2, próximamente más h…
RT @DomingoPascualF: Estamos intentando descifrar los mecanismos del beneficio de los probablemente mal llamados iSGLT2, próximamente más h…
Estamos intentando descifrar los mecanismos del beneficio de los probablemente mal llamados iSGLT2, próximamente más hallazgos!
RT @ValleAlfonso: Via @JACCJournals @secardiologia @yulnunezvill @DomingoPascualF Dr Lupón, Dr Bayés-Genís & cia 📎https://t.co/yGMieSRWoK
RT @AnastasiaSMihai: Not sure how I missed👇but❤️@JACCJournals #JACCBTS Unraveling Molecular Mechanism of Action of Empagliflozin in #HFrE…
RT @ValleAlfonso: Via @JACCJournals @secardiologia @yulnunezvill @DomingoPascualF Dr Lupón, Dr Bayés-Genís & cia 📎https://t.co/yGMieSRWoK
RT @AnastasiaSMihai: Not sure how I missed👇but❤️@JACCJournals #JACCBTS Unraveling Molecular Mechanism of Action of Empagliflozin in #HFrE…
ネズミたんの心臓の向きとんでもねーことになっとる
Not sure how I missed👇but❤️@JACCJournals #JACCBTS Unraveling Molecular Mechanism of Action of Empagliflozin in #HFrEF With or Without #Diabetes https://t.co/HEefPobTzM Would have been interesting to see the effect on autophagy as well as apoptosis https
RT @ValleAlfonso: Via @JACCJournals @secardiologia @yulnunezvill @DomingoPascualF Dr Lupón, Dr Bayés-Genís & cia 📎https://t.co/yGMieSRWoK
RT @ValleAlfonso: Via @JACCJournals @secardiologia @yulnunezvill @DomingoPascualF Dr Lupón, Dr Bayés-Genís & cia 📎https://t.co/yGMieSRWoK
RT @ChadSWeldy: Fantastic work examining the molecular mechanism of Empagliflozin on HF - benefit is not about SGLT2i, but inhibiting cardi…
Fantastic work examining the molecular mechanism of Empagliflozin on HF - benefit is not about SGLT2i, but inhibiting cardiac NHE1, blocking myocyte apoptosis. Wonderful method of using human RNAseq data, AI, then animal model validation https://t.co/JHqc
Via @JACCJournals @secardiologia @yulnunezvill @DomingoPascualF Dr Lupón, Dr Bayés-Genís & cia 📎https://t.co/yGMieSRWoK
RT @santi_roura: Impressive work @Oratioscientiae and colleagues!! Congrats!! https://t.co/TpRz1WFgIy
Impressive work @Oratioscientiae and colleagues!! Congrats!!
RT @salvareverentia: Great work @Oratioscientiae!!! Thanks for involving me in this project ;) https://t.co/ElAuuwMteu
Great work @Oratioscientiae!!! Thanks for involving me in this project ;) https://t.co/ElAuuwMteu
RT @ElyGraciaMD: Proposed mechanism for Empagliflozin’s effect on HFrEF! Perhaps the days of SGLT2-i as primary DM therapy with off-target…
Pre-clinical yet provoking. Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes https://t.co/ZkLWHSWVqa
@anish_koka @MKIttlesonMD @ChristosArgyrop That the benefit appears to not be driven by diuresis. Cant really expect all of that from 0.8 kg. That other mechanisms lead to the better outcomes. Largely unknown, but brilliant papers like this are giving ins
RT @ElyGraciaMD: Proposed mechanism for Empagliflozin’s effect on HFrEF! Perhaps the days of SGLT2-i as primary DM therapy with off-target…
RT @hswapnil: @aishaikh @nature Yesterday it was this for the heart https://t.co/iJyjCiDPHu 🤷🏽♂️
RT @hswapnil: @aishaikh @nature Yesterday it was this for the heart https://t.co/iJyjCiDPHu 🤷🏽♂️
@aishaikh @nature Yesterday it was this for the heart https://t.co/iJyjCiDPHu 🤷🏽♂️
RT @ElyGraciaMD: Proposed mechanism for Empagliflozin’s effect on HFrEF! Perhaps the days of SGLT2-i as primary DM therapy with off-target…
RT @ElyGraciaMD: Proposed mechanism for Empagliflozin’s effect on HFrEF! Perhaps the days of SGLT2-i as primary DM therapy with off-target…
Great read to better understand the effect of SGLT2s w/in HFrEFers
RT @ElyGraciaMD: Proposed mechanism for Empagliflozin’s effect on HFrEF! Perhaps the days of SGLT2-i as primary DM therapy with off-target…
RT @ElyGraciaMD: Proposed mechanism for Empagliflozin’s effect on HFrEF! Perhaps the days of SGLT2-i as primary DM therapy with off-target…
RT @ElyGraciaMD: Proposed mechanism for Empagliflozin’s effect on HFrEF! Perhaps the days of SGLT2-i as primary DM therapy with off-target…
RT @ElyGraciaMD: Proposed mechanism for Empagliflozin’s effect on HFrEF! Perhaps the days of SGLT2-i as primary DM therapy with off-target…
RT @ElyGraciaMD: Proposed mechanism for Empagliflozin’s effect on HFrEF! Perhaps the days of SGLT2-i as primary DM therapy with off-target…
RT @ElyGraciaMD: Proposed mechanism for Empagliflozin’s effect on HFrEF! Perhaps the days of SGLT2-i as primary DM therapy with off-target…
RT @ElyGraciaMD: Proposed mechanism for Empagliflozin’s effect on HFrEF! Perhaps the days of SGLT2-i as primary DM therapy with off-target…
Proposed mechanism for Empagliflozin’s effect on HFrEF! Perhaps the days of SGLT2-i as primary DM therapy with off-target cardiac effects are numbered! @SVijayakumarMD @md_harrington @JavedButler1 https://t.co/D1qBHKIFbn